key: cord-1050801-yaoypo6x authors: Miyabe, Yui; Kobayashi, Yoshiki; Fukuchi, Mineyo; Saga, Akiko; Moritoki, Yuki; Saga, Tomoo; Akuthota, Praveen; Ueki, Shigeharu title: Eosinophil-mediated inflammation in the absence of eosinophilia date: 2021-07-13 journal: Asia Pac Allergy DOI: 10.5415/apallergy.2021.11.e30 sha: 4bfa0f106f772036fa4021eaddf77775a3c3d1e2 doc_id: 1050801 cord_uid: yaoypo6x The increase of eosinophil levels is a hallmark of type-2 inflammation. Blood eosinophil counts act as a convenient biomarker for asthma phenotyping and the selection of biologics, and they are even used as a prognostic factor for severe coronavirus disease 2019. However, the circulating eosinophil count does not always reflect tissue eosinophilia and vice versa. The mismatch of blood and tissue eosinophilia can be seen in various clinical settings. For example, blood eosinophil levels in patients with acute eosinophilic pneumonia are often within normal range despite the marked symptoms and increased number of eosinophils in bronchoalveolar lavage fluid. Histological studies using immunostaining for eosinophil granule proteins have revealed the extracellular deposition of granule proteins coincident with pathological conditions, even in the absence of a significant eosinophil infiltrate. The marked deposition of eosinophil granule proteins in tissue is often associated with cytolytic degranulation. Recent studies have indicated that extracellular trap cell death (ETosis) is a major mechanism of cytolysis. Cytolytic ETosis is a total cell degranulation in which cytoplasmic and nuclear contents, including DNA and histones that act as alarmins, are also released. In the present review, eosinophil-mediated inflammation in such mismatch conditions is discussed. Allergy, a hypersensitivity reaction initiated by specific immunologic mechanisms [1] , is often associated with tissue eosinophilia [2] . In addition, eosinophil accumulation is also associated with malignancy, infection, and various homeostatic conditions. For example, eosinophils home into the uterus, which is regulated by the estrus cycle [3, 4] . Eosinophils in the blood can be readily counted. Although these cells form a minor (<5%) component of the circulating leukocyte population in the blood, larger numbers of tissue-dwelling eosinophils are present outside of the vasculature [5] . Nevertheless, the blood eosinophil count is an easy-to-access biomarker for various clinical applications. For asthma phenotyping and the selection of biologics, the blood eosinophil count is the best-established biomarker [6] . In patients with severe chronic obstructive diseases, blood eosinophil counts are associated with the risk of exacerbations and the benefit of inhaled corticosteroid use [7] . A lower blood eosinophil count is also useful as a poor prognostic factor for severe coronavirus disease 2019 [8, 9] . Eosinophils develop in the bone marrow and are released into blood circulation once they are maturated. Circulating eosinophils can subsequently transmigrate into the gastrointestinal tract, lungs, adipose tissue, thymus, spleen, lymph nodes, and mammary glands, where they exert various essential homeostatic functions [10, 11] . The life span of eosinophils is unclear, but it has been estimated to be less than 1 week under homeostatic conditions [12] . The tissue presence of eosinophils is determined by their recruitment, retention, and clearance [13] . Therefore, tissue eosinophilia can be caused by increased migration, prolonged survival, impaired phagocytic clearance, or decreased luminal entry [14] . The activation status of eosinophils is mainly tuned by receptors expressed on their cell surfaces. As a short-lived, nondividing cell, eosinophil "activation" has been recognized as the release of bioactive mediators into the extracellular milieu [15] . This is in contrast to lymphocytes, for which "activation" usually means proliferation and clonal expansion of antigen-specific lymphocytes [16] . The multifaceted role of eosinophils is evidenced by their range of cell densities and cell-derived mediators. Because eosinophils are a rich source of bioactive mediators, the simplified hypothesis is that the amount of eosinophil-derived inflammatory mediators in the microenvironment is the primary cause of eosinophilic inflammation. Eosinophils contain approximately 200 granules per cell [17] . These granules contain 4 major cationic (basic) proteins, that is, major basic protein (MBP), eosinophil-derived neurotoxin (EDN), eosinophil cationic protein (ECP), and eosinophil peroxidase (EPO), which play important roles in eosinophil-mediated inflammation [18] . Granule-stored cytokines in human eosinophils are released by 3 secretory processes: classical exocytosis, piecemeal degranulation, and cytolysis/extracellular trap cell death (ETosis) [5, 19] . Classical exocytosis is a granule secretory system in which intracellular granules fuse with the plasma membrane and release their entire contents extracellularly via a secretory pore. This mechanism is not usually observed in vivo. In compound exocytosis, granules fuse to each other, forming large channels within the cytoplasm, and the cells then secrete the entire intragranular contents of multiple granules [18] . Piecemeal degranulation is thought to be the main degranulation process used by eosinophils. In piecemeal degranulation, the granule contents are selectively mobilized into small round vesicles and tubular structures termed eosinophil sombrero vesicles. The tubular eosinophil sombrero vesicles express cytokine receptor chains that are bound by cytokine ligands, such as interleukin (IL)-4 [5] . These vesicles become fused with the plasma membrane and release their granule-derived contents into extracellular spaces [20, 21] . Ultrastructure of exocytosis and piecemeal degranulation show an emptying of the secretory granules or lucent areas in the core of intact eosinophils [18] . Cytolysis or ETosis is a recently recognized type of programmed cell death that is characterized by the dissolution of nuclear and plasma membranes and release of chromatin fiber called an extracellular trap [22] [23] [24] . In eosinophils, ETosis-derived cell-free extracellular granules express functional receptors on their membranes [18, 19, 25, 26] . Upon activation by ligand stimulation, the granules release their contents, which include EDN [27, 28] . Eosinophil ETosis (EETosis) is considered to contribute to the sterilization and trapping of pathogens by extracellular traps, granule proteins, and nuclear-derived components, all of which have cytotoxicity [29, 30] . The functions of the major mediators derived from human eosinophils are summarized in Table 1 . MBP-stimulated normal human bronchial epithelial cells have elevated expression levels of endothelin-1, transforming growth factor (TGF)-α, TGF-β, plateletderived growth factor, matrix metallopeptidase 9, and fibronectin, which suggests that MBP affects the composition of the extracellular matrix and turnover of airway epithelium [48] . MBP was also suggested to enhance bronchoconstriction in asthma through blocking muscarinic M2 receptors, followed by eliminating the negative feedback and increasing the release of acetylcholine [49]. . ECP is also involved in fibrinolysis via plasminogen enhancement [65] . Additionally, ECP inhibits microbial activity by forming amyloid-like aggregates on bacterial surfaces [66] . In a recent report, ECP and EDN both induced the expression of matrix metalloproteinase 9 in keratinocytes and triggered keratinocyte apoptosis, which suggests their potential as therapeutic targets for bullous pemphigoid [67] . EPO is highly cationic, heme-containing oxidoreductase that is similar to myeloperoxidase (MPO) in neutrophils [68] . Although EPO and MPO have 68.3% of the same amino acids [69] , there are some differences in their functions; for example, EPO binds to antineutrophil cytoplasmic antibodies and is involved in renal fibrosis [70, 71] . EPO is taken up by neutrophils, basophils, and mast cells, and EPO has a higher affinity for neutrophils compared with MPO [72, 73] . By acting as an oxidoreductase, halides are coactivated with reactive oxygen species to produce hypochlorous acid, which is highly toxic to helminth parasites and bacteria [74, 75] as well as toxic to tumor cells [76] . Hypothiocyanous acid (HOSCN) is produced by the oxidation of EPO and induces tissue factor activation, which suggests its involvement in thrombosis. HOSCN also activates the proinflammatory p65/p50 nuclear factor-κB pathway [77] . EPO binds to the surface of microorganisms, thereby facilitating macrophage phagocytosis even in microorganisms that are resistant to macrophage destruction [78] . EPO is associated with mucus plugging of the airways in asthma [79] . Similar to MBP and ECP, EPO induces mast cell degranulation [80] . EPO also inactivates leukotrienes B4, C4, and D4 [81]. Galectin-10 is a cytoplasmic protein that belongs to S-lectin family and the fifth most abundant protein in eosinophils [50] . It was originally recognized as Charcot-Leyden crystal (CLC) protein and later named galectin-10 because of its carbohydrate-binding domain, which is similar to those of other galectin family members. Galectin-10 is expressed predominantly on eosinophils but is also present on macrophages, basophils, and CD4 + CD25 + regulatory T cells EETosis releases eosinophil extracellular traps, which are composed mainly of histones and double-stranded DNA, that is, chromatin fiber. Eosinophil extracellular traps are effective at trapping microbial pathogens because of their net-like structure [89] . A proteome analysis of human eosinophils indicated that histones ranked 3rd, 4th, 6th, and 15th in abundance among the top 15 proteins [50] . The cytotoxic effects to bacteria of histones have been known for more than 50 years [90] . Histones promote cell apoptosis [91, 92] and are involved in inflammation by stimulating Toll-like receptor signaling pathways [93] [94] [95] or NLRP3 inflammasomes [96, 97] . Histones have also been recognized as inducers of the blood coagulation system [98] [99] [100] [101] . Extracellular double-stranded DNA is known to cause vascular damage [102, 103] and thrombosis, and it can stimulate autoimmune responses, such as systemic lupus erythematosus [104] [105] [106] . Eosinophils are a rich source of cysteinyl leukotrienes (cysLTs). Leukotriene C4 and its metabolites, leukotriene D4 and leukotriene E4, have varied roles in mediating eosinophilic disorders, including host defense against parasites and allergic inflammation. CysLTs can activate eosinophils in an autocrine manner (they prolong survival), and induce reactive oxygen species production and EDN release from eosinophils [107, 108] . CysLTs are also involved in eosinophil differentiation and maturation in combination with IL-5 [109] . Additionally, extracellular eosinophil granules can release ECP in response to cysLT stimulation via cysLT receptors expressed on the granule membrane [110] . 6/22 https://apallergy.org https://doi.org/10.5415/apallergy.2021.11.e30 Eosinophils store a wide array of cytokines, chemokines, and growth factors, including IL-4 [111, 112] , granulocyte macrophage colony-stimulating factor (GM-CSF) [113] [114] [115] , and TGF-β [116] [117] [118] . IL-4 induces eosinophil migration into tissues via the expression of adhesion molecule vascular cell adhesion molecule-1 on endothelial cells [119] . Various stimuli, including calcium ionophore [113, 114] and fibronectin [115] , can induce GM-CSF production in eosinophils. GM-CSF is involved in the type-2 response in allergic airway inflammation through activating dendritic cells and enhancing eosinophil survival in an autocrine manner [120, 121] . Peripheral blood eosinophilia can assist in the diagnosis of eosinophilic inflammatory diseases, including eosinophilic pneumonia. Unlike the diagnostic criteria for chronic eosinophilic pneumonia with peripheral blood eosinophilia, the diagnostic criteria for acute eosinophilic pneumonia (AEP) do not require peripheral blood eosinophilia [122] . AEP is caused mainly by inhalational exposure, such as cigarette smoke, including electronic cigarettes or heated tobacco [123] , and develops acutely along with respiratory failure. Peripheral blood eosinophilia may be absent at the onset of AEP, especially in smoking-related AEP [124] . We experienced a case in which bacterial pneumonia was suspected because of the patient's neutrophilia, and the results of a bronchoalveolar lavage led to the diagnosis of AEP. A 21-year-old woman had fever and dyspnea 1 week after smoking initiation. Upon hospitalization, she was febrile (39.6°C) and tachypneic with a reduced peripheral oxygen saturation (91%). Her arterial blood gases under room air were: pH, 7.44; PaO 2 , 55 mmHg; and PaCO 2 , 30 mmHg. Her chest x-ray showed bilateral ground grass attenuations mixed with consolidations and a slight pleural effusion. The laboratory test revealed a white blood cell count of 23,400 cells/µL with neutrophilia (95.8%, 22,417 cells/µL). Her serum C-reactive protein level was 8.2 mg/dL (normal, <0.3 mg/dL), IL-5 level was 1,012 pg/mL (normal, <3.9 pg/mL), and ECP level was 68.9 µg/L (normal, <14.9 µg/L), and her peripheral blood eosinophil count was only 94 cells/µL. Conversely, a marked elevation of eosinophils was observed in her bronchoalveolar lavage fluid (71% eosinophils in the differential cell count), leading to the diagnosis of AEP. A single administration of methylprednisolone (40 mg) and the cessation of cigarette smoking dramatically improved the symptoms of AEP. Notably, in parallel with the patient's improvement of bilateral pulmonary infiltration, her peripheral eosinophil counts reached up to 1,250 cells/µL on day 9 (6 days after methylprednisolone administration) (Fig. 1A, B) . Before or during eosinophil movement, a cellular shape change related to migration is necessary [2] . We conducted an ex vivo eosinophil shape change assay by using flow cytometric measurement of autofluorescence/forward scatter on cells stimulated with cigarette smoke extract [125] . A clear shape change was induced in the patient's eosinophils at the onset, and such changes were not reproduced in cells taken from the patient after the resolution of AEP or in eosinophils from a normal donor (Fig. 1C) . Thus, it can be speculated that eosinophils have the potential to accumulate in the lung at the onset of AEP. IL-5 plays a critical role in an eosinophilopoiesis, chemokinesis/chemotaxis, integrin activation, and survival prolongation via apoptosis inhibition [6] . In our case, the initially 7/22 https://apallergy.org https://doi.org/10.5415/apallergy.2021.11.e30 Eosinophil-mediated inflammation elevated serum IL-5 level was associated with AEP disease severity, despite the peripheral blood eosinophil counts being in the normal range. Interestingly, serum IL-5 levels have been shown to inversely correlate with peripheral blood eosinophil counts in patients in the initial state of AEP [126] . This is likely caused by the rapid migration of blood eosinophils to the lungs, as illustrated in Fig. 2A . Notably, the pathological condition of asthma was recreated in lung-specific IL-5 transgenic mice but not in "systemic" IL-5 transgenic mice [6] . Tissuespecific overproduction of IL-5 might play an important role in the pathogenesis of AEP by recruiting eosinophils from the peripheral blood into the lungs. In patients with atopic asthma, sputum eosinophil counts and serum IL-5 levels increase after allergen inhalation, whereas blood eosinophil counts decrease for 12 hours [127, 128] . The intravascular residence time of radiolabeled eosinophils in healthy volunteers is approximately 25 hours, although it can be 1.5 hours in a patient with tissue eosinophilic inflammation [129, 130] . Accumulated eosinophils might directly induce eosinophilia through the production of eosinophil chemoattractants, such as leukotriene B4 [131] and C-C chemokine ligand 4 [132] . These data suggest that a dynamic shift of circulating eosinophils into the tissue can occur. Transient blood eosinophilia after systemic corticosteroid administration is another interesting feature of the present case. This phenomenon has been reported previously; ) . On day 2, the patient was treated with an intravenous administration of methylprednisolone (mPSL). (B) Chest x-ray on day 2 (before performing a bronchoalveolar lavage and mPSL administration) and day 9 (6 days after treatment). (C) Response of eosinophils to cigarette smoke extract (CSE). CSE was prepared as described by a previous report [161] . Peripheral whole blood cells stimulated with CSE for 10 minutes and red blood cells were lysed using BD FACS Lysing Solution (BD Biosciences, San Jose, CA, USA). The eosinophil shape change induced by CSE was evaluated using a FACScan flow cytometer (BD Biosciences). Values shown are the % of control buffer. HV, healthy volunteer. serum IL-5 rapidly falls into the normal range within 10 days [126] , whereas peripheral blood eosinophil counts increase with radiographic and clinical resolution during the following days [126, 133, 134] . Corticosteroids have various potent anti-inflammatory effects on allergic inflammation. They can induce eosinophil apoptosis directly as well as can indirectly, by inhibiting the production of survival factors including IL-5 [135, 136] . In addition, corticosteroids enhance the phagocytic capacity of macrophages and airway epithelial cells [136, 137] . Apoptotic eosinophils are intact when they are recognized and engulfed by phagocytes, so they do not induce inflammation [138] . As illustrated in Fig. 2B , after the treatment of AEP with a systemic steroid, eosinophilic lung inflammation is resolved, likely through the clearance of apoptotic eosinophils in the lungs. It is also conceivable that the decreased recruitment of blood eosinophils into the lungs results in a transient blood eosinophilia. The mismatch of circulating and tissue eosinophilia is not limited to AEP. For instance, we have also experienced a case in which a patient with GM-CSF-producing lung cancer showed no clinical manifestations or evidence of tissue eosinophilia despite having marked blood eosinophilia (>30,000 cells/µL) [139] . Dupilumab, an anti-IL-4Ra antibody that blocks both IL-4 and IL-13 signaling, can trigger eosinophilia without the presentation of clinical signs of organ involvement owing to eosinophil infiltration [140] . The mechanisms underlying dupilumab-induced eosinophilia remain unknown, but it has been hypothesized that dupilumab blocks the migration of eosinophils into tissue without blocking eosinophil production in the bone marrow [141] . Hypereosinophilia is defined by a peripheral blood absolute eosinophil count of greater than 1,500 cells/µL that may not be associated with tissue damage [142] . In addition to patients with hypereosinophilic syndrome, who typically require treatment to prevent disease progression, there are patients with unexplained persistent asymptomatic hypereosinophilia. Additionally, clinical manifestation related to eosinophilic inflammation is uncommon in patients with familial eosinophilia [143] . Thus, the circulating eosinophil count does not always reflect tissue eosinophilia and vice versa. Tissue hypereosinophilia can be defined as tissue with a percentage of eosinophils that exceeds 20% of all nucleated cells in the bone marrow or tissue infiltration that is deemed extensive by a pathologist [11, 144] . However, historical studies with immunostaining for eosinophil granule proteins have revealed the extracellular deposition of granule proteins coincident with pathological conditions, even in the absence of a significant eosinophil infiltrate. Frigas ans Gleich [145] described the lung tissue specimens from autopsy cases who died of asthma as follows: "some eosinophils were intact, others were partially degranulated and surrounded by their extruded granules, and others were totally disrupted and unrecognizable by hematoxylin and eosin stain." In atopic patients challenged with an intradermal injection of allergen, MBP and EDN were extensively deposited throughout the dermis in the late-phase reaction [146] . Tissue deposition of granule protein in the absence of eosinophil accumulation has also been reported by Gleich et al. in cases of Hodgkin's disease [147] , parasite infection [148, 149] , chronic urticaria [150] , atopic dermatitis [151] , and endomyocardial disease [152] . Several studies have indicated that granule protein deposition, rather than intact eosinophils, is associated with tissue remodeling [153, 154] . Given the toxicity of eosinophil granule proteins, histologic evidence of extracellular granule protein deposition in the tissue might be a more appropriate marker for inflammation than tissue eosinophilia. Our group has studied hundreds of tissues from patients with allergic or eosinophilic diseases [26, 29, 83, 84, [155] [156] [157] [158] [159] [160] . In our tissue immunostaining experience, like Gleich et al., we have observed that the extracellular deposition of MBP is not disease-specific, but it is closely associated with tissue damage and the presence of eosinophil cytolysis. Fig. 3 shows a typical example: surgically obtained nasal polyps from a case of chronic rhinosinusitis with nasal polyps (eosinophilic chronic rhinosinusitis). Hematoxylin and eosin staining revealed that the accumulated eosinophils were cytolytic, showing extracellular cell-free granules and chromatolysis and/or a loss of nuclear envelope. Immunostaining indicated a massive deposition of extracellular MBP that is consistent with the presence of cytolytic eosinophils. These cytolytic eosinophils were ultrastructurally identical to EETosis induced by various stimuli in vitro [26, 83] . Apoptosis facilitates the ingestion of intact eosinophils without a disgorgement of their toxic contents, and this process is necessary for the normal resolution of inflammation [138] . Impaired phagocytic clearance (efferocytosis) of lytic eosinophils is a critical feature of persistent inflammation. Notably, efferocytosis by phagocytic cells might not be applicable for ETotic cells, because of their rapid cell death process (0.5-3 hours) and lack of find-me signal exposure before cell lysis [25, 26] . Therefore, eosinophil cell fate within tissues might have completely different consequences (Fig. 4) . The presence of eosinophils is an important feature of type-2 inflammation, but clinical observations have indicated that eosinophil-mediated inflammation is not always coincident with an increase in eosinophil counts. As shown in the case of AEP, there are various examples of mismatch between the circulating eosinophil count and clinical manifestation. As stated above, considerable evidence has indicated that the marked deposition of eosinophil granule proteins in tissue is associated with tissue damage and remodeling. The most important feature of eosinophils as end-stage effector cells is their activation to release Eosinophils apoptosis can be caused by many factors, including aging, a loss of survival factors, corticosteroids, and anti-interleukin (IL)-5/anti-IL-5 receptor antibodies. Apoptotic eosinophils, typically with nuclear and cytoplasmic condensation, are phagocytosed without the induction of inflammation. Alternately, eosinophils can undergo ETosis upon activation, such as by an immunoglobulin-coated surface, pathogens, or platelet-activating factor with IL-5. Rapid cytolysis without the expression of a "find-me" signal results in the tissue deposition of the cell's total intracellular contents and prolonged inflammation. toxic cellular contents. In this context, eosinophils can be innocent bystanders without the secretion of their bioactive mediators. EETosis is now considered to be a major mechanism of cytolytic degranulation. This process is not only a total cell degranulation but also a release of cytoplasmic and nuclear contents, including DNA and histones that act as alarmins. Although the maintenance of tissue eosinophils is tightly related to the ability of the cell and the microenvironment to maintain an appropriate balance between survival and active cell death pathways, it is not yet fully understood. Further study will lead to a better understanding of eosinophil-mediated inflammation and its treatment. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization Soluble vascular cell adhesion molecule-1 induces human eosinophil migration Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus Expression and functional roles of G-protein-coupled estrogen receptor (GPER) in human eosinophils Functions of tissue-resident eosinophils The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis What can we learn from blood granulocyte patterns in patients with asthma? Enhancement of urokinase-induced plasminogen activation by the cationic protein of human eosinophil granulocytes Exploring new biological functions of amyloids: bacteria cell agglutination mediated by host protein aggregation Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil-derived neurotoxin on human keratinocytes Thiocyanate-dependent induction of endothelial cell adhesion molecule expression by phagocyte peroxidases: a novel HOSCN-specific oxidant mechanism to amplify inflammation Molecular cloning of the human eosinophil peroxidase. Evidence for the existence of a peroxidase multigene family Eosinophil peroxidase differs from neutrophil myeloperoxidase in its ability to bind antineutrophil cytoplasmic antibodies reactive with myeloperoxidase Peroxidasin and eosinophil peroxidase, but not myeloperoxidase, contribute to renal fibrosis in the murine unilateral ureteral obstruction model Uptake of human eosinophil peroxidase by human neutrophils Vesicular uptake of eosinophil peroxidase by guinea pig basophils and by cloned mouse mast cells and granule-containing lymphoid cells Human neutrophil-mediated killing of schistosomula of Schistosoma mansoni: augmentation by schistosomal binding of eosinophil peroxidase Human eosinophilic peroxidase: role in bactericidal activity Eosinophil-mediated mammalian tumor cell cytotoxicity: role of the peroxidase system The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states Arming of mononuclear phagocytes by eosinophil peroxidase bound to Staphylococcus aureus National Heart Lung and Blood Institute (NHLBI) Severe Asthma Research Program (SARP) Eosinophil peroxidase-induced mast cell secretion Neutrophil extracellular traps: double-edged swords of innate immunity Bactericidal action of histone Histone 3.3 participates in a self-sustaining cascade of apoptosis that contributes to the progression of chronic obstructive pulmonary disease Extracellular histone H1 is neurotoxic and drives a pro-inflammatory response in microglia Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice Toxic effects of extracellular histones and their neutralization by vitreous in retinal detachment Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4 Histones trigger sterile inflammation by activating the NLRP3 inflammasome Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury Histones induce rapid and profound thrombocytopenia in mice Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation Functional responses and molecular mechanisms involved in histone-mediated platelet activation Histone induced platelet aggregation is inhibited by normal albumin Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus Netting neutrophils in autoimmune small-vessel vasculitis Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals Leukotriene D4 and eosinophil transendothelial migration, superoxide generation, and degranulation via beta2 integrin Effects of a cysteinyl leukotriene receptor antagonist on eosinophil recruitment in experimental allergic rhinitis Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules Functional analysis of free fatty acid receptor GPR120 in human eosinophils: implications in metabolic homeostasis Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils Adhesion to fibronectin prolongs eosinophil survival Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation Eosinophil-associated TGF-β1 mRNA expression and airways fibrosis in bronchial asthma Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1 IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF) Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33 Eosinophilic pneumonias Acute eosinophilic pneumonia and heated tobacco products Acute eosinophilic pneumonia causes, diagnosis, and management Physiological levels of 15-deoxy-Delta12,14-prostaglandin J2 prime eotaxin-induced chemotaxis on human eosinophils through peroxisome proliferator-activated receptor-gamma ligation Clinical implications of correlation between peripheral eosinophil count and serum levels of IL-5 and tryptase in acute eosinophilic pneumonia Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation Use of technetium-99m-labeled eosinophils to detect active eosinophilic inflammation in humans Use of 111-Indium-labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects Leukotriene B4 amplifies eosinophil accumulation in response to nematodes Critical role of CCL4 in eosinophil recruitment into the airway Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management Idiopathic acute eosinophilic pneumonia: a study of 22 patients Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action Eosinophils in the lung -modulating apoptosis and efferocytosis in airway inflammation Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5 Unusual morphologies of blood eosinophils in GM-CSF-producing lung cancer Groupe de Recherche sur l'Eczéma aTopique (GREAT), France. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management Dysregulation of interleukin 5 expression in familial eosinophilia An approach to the evaluation of persistent hypereosinophilia in pediatric patients The eosinophil and the pathophysiology of asthma Extracellular deposition of eosinophil and neutrophil granule proteins in the IgE-mediated cutaneous late phase reaction Extracellular deposition of eosinophil granule major basic protein in lymph nodes of patients with Hodgkin's disease Localization of eosinophil major basic protein onto eggs of Schistosoma mansoni in human pathologic tissue Eosinophil-mediated inflammation Deposition of eosinophil granule major basic protein onto microfilariae of Onchocerca volvulus in the skin of patients treated with diethylcarbamazine Localization of eosinophil granule major basic protein in chronic urticaria Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration Eosinophil granule protein localization in eosinophilic endomyocardial disease Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis Deposition of eosinophil-granule major basic protein and expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the mucosa of the small intestine in infants with cow's milk-sensitive enteropathy Eosinophilic cholecystitis occurred in a patient with refractory eosinophilic airway inflammation: a case report Focal eosinophilic myositis with Charcot-Leyden crystal formation Sialodochitis fibrinosa: Salivary duct obstruction by eosinophil extracellular traps? An unusual case of eosinophilic lung disease with multiple cyst formation Hypereosinophilic syndrome with abundant Charcot-Leyden crystals in spleen and lymph nodes How to detect eosinophil ETosis (EETosis) and extracellular traps Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: implications for steroid resistance Interactions between human eosinophils and schistosomula of schistosoma mansoni. II. The mechanism of irreversible eosinophil adherence The biology of the eosinophilic leukocyte Donor sensitivity to basophil activation by eosinophil granule major basic protein Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X Eosinophil cationic protein and eosinophil-derived neurotoxin. Evolution of novel function in a primate ribonuclease gene family Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function Functional role of the interaction between polysialic acid and extracellular histone H1 Extracellularly occurring histone H1 mediates the binding of thyroglobulin to the cell surface of mouse macrophages Extracellular histones are major mediators of death in sepsis Extracellular histones are essential effectors of C5aR-and C5L2-mediated tissue damage and inflammation in acute lung injury Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4 Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis Extracellular DNA traps promote thrombosis Ramsey PG, et al. J Immunol 1982;128:415-20. [78] Mediates mucus plugging of the airways Dunican The authors are grateful to Noriko Tan for technical assistance and Satomi Misawa for outstanding assistance in drawing the figures. They also thank Katie Oakley, PhD, from Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript. For all clinical samples, written informed consent was obtained from all participants in accordance with the Declaration of Helsinki and institutional review board-approved protocols.